share_log

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

諾和諾德 | 6-K：2024年1月1日至3月31日期間的財務報告
美股sec公告 ·  05/02 07:18
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a robust financial performance for the first quarter of 2024. The company's sales surged by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion. The operating profit followed suit, increasing by 27% in Danish kroner and 30% at CER to DKK 31.8 billion. North America Operations, particularly the US market, contributed significantly to this growth with a 34% increase in sales. The company's Diabetes and Obesity care segment saw a 25% rise in sales, driven by GLP-1 diabetes sales and Obesity care. However, rare disease sales experienced a slight decline. Notably, Novo Nordisk completed the FLOW kidney outcomes trial and received US approval for Wegovy for cardiovascular risk reduction...Show More
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a robust financial performance for the first quarter of 2024. The company's sales surged by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion. The operating profit followed suit, increasing by 27% in Danish kroner and 30% at CER to DKK 31.8 billion. North America Operations, particularly the US market, contributed significantly to this growth with a 34% increase in sales. The company's Diabetes and Obesity care segment saw a 25% rise in sales, driven by GLP-1 diabetes sales and Obesity care. However, rare disease sales experienced a slight decline. Notably, Novo Nordisk completed the FLOW kidney outcomes trial and received US approval for Wegovy for cardiovascular risk reduction. Additionally, the company announced an agreement to acquire three fill-finish sites from Novo Holdings A/S. Looking ahead, Novo Nordisk has raised its 2024 outlook, expecting sales growth of 19-27% and operating profit growth of 22-30% at CER. The company's financial report was prepared in accordance with IAS 34 'Interim Financial Reporting' and Danish disclosure requirements.
糖尿病護理領域的全球醫療保健領導者諾和諾德A/S報告了2024年第一季度的強勁財務表現。該公司的銷售額以丹麥克朗計算增長了22％，按固定匯率（CER）計算增長了24％，達到653億丹麥克朗。營業利潤緊隨其後，按丹麥克朗計算增長了27％，按CER計算增長了30％，達到318億丹麥克朗。北美業務，尤其是美國市場，爲這一增長做出了重大貢獻，銷售額增長了34％。在 GLP-1 糖尿病銷售和肥胖護理的推動下，該公司的糖尿病和肥胖護理板塊的銷售額增長了25％。但是，罕見病的銷售額略有下降。值得注意的是，諾和諾德完成了FLOW腎臟預後試驗，並獲得了美國批准的Wegovy用於降低心血管風險。此外，該公司宣佈了...展開全部
糖尿病護理領域的全球醫療保健領導者諾和諾德A/S報告了2024年第一季度的強勁財務表現。該公司的銷售額以丹麥克朗計算增長了22％，按固定匯率（CER）計算增長了24％，達到653億丹麥克朗。營業利潤緊隨其後，按丹麥克朗計算增長了27％，按CER計算增長了30％，達到318億丹麥克朗。北美業務，尤其是美國市場，爲這一增長做出了重大貢獻，銷售額增長了34％。在 GLP-1 糖尿病銷售和肥胖護理的推動下，該公司的糖尿病和肥胖護理板塊的銷售額增長了25％。但是，罕見病的銷售額略有下降。值得注意的是，諾和諾德完成了FLOW腎臟預後試驗，並獲得了美國批准的Wegovy用於降低心血管風險。此外，該公司宣佈了一項從Novo Holdings A/S手中收購三處填充場地的協議。展望未來，諾和諾德上調了其2024年的展望，預計CER的銷售額將增長19-27％，營業利潤增長22-30％。該公司的財務報告是根據國際會計準則第34號 “中期財務報告” 和丹麥的披露要求編制的。

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息